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A B S T R A C T
The extracellular signal-regulated kinases (ERKs) serve as important determinants of cellular signal transduction
pathways, and hence may play important roles during infections. Previous work suggested that putative ERK7 of
Toxoplasma gondii is required for efficient intracellular replication of the parasite. However, the antigenic and
immunostimulatory properties of TgERK7 protein remain unknown. The objective of this study was to produce a
recombinant TgERK7 protein in vitro and to evaluate its effect on the induction of humoral and T cell-mediated
immune responses against T. gondii infection in BALB/c mice. Immunization using TgERK7 mixed with Freund's
adjuvants significantly increased the ratio of CD3e+CD4+ T/CD3e+CD8a+ T lymphocytes in spleen and ele-
vated serum cytokines (IFN-γ, IL-2, IL-4, IL-10, IL-12p70, IL-23, MCP-1, and TNF-α) in immunized mice com-
pared to control mice. On the contrary, immunization did not induce high levels of serum IgG antibodies. Five
predicted peptides of TgERK7 were synthesized and conjugated with KLH and used to analyze the antibody
specificity in the sera of immunized mice. We detected a progressive increase in the antibody level only against
TgERK7 peptide A (DEVDKHVLRKYD). Antibody raised against this peptide significantly decreased intracellular
proliferation of T. gondii in vitro, suggesting that peptide A can potentially induce a protective antibody response.
We also showed that immunization improved the survival rate of mice challenged with a virulent strain and
significantly reduced the parasite cyst burden within the brains of chronically infected mice. Our data show that
TgERK7-based immunization induced TgERK7 peptide A-specific immune responses that can impart protective
immunity against T. gondii infection. The therapeutic potential of targeting ERK7 signaling pathway for future
toxoplasmosis treatment is warranted.
1. Introduction
The apicomplexan protozoan parasite Toxoplasma gondii is an op-
portunistic protozoan that can infect all warm-blooded animals and
approximately one-third of the world’s human population (Chen et al.,
2017; Kim and Weiss, 2008; Sasai et al., 2018; Schlüter et al., 2014). T.
gondii infection can result in serious illness particularly in infants in-
fected in utero and in immunocompromised patients (Elsheikha, 2008).
This parasite secretes proteins (e.g. cyclophilin-18, TgMIF and heat-
shock cognate protein 70 T) to manipulate host cell machinery in order
to sustain its own growth and survival within the host (Dvorakova-
Hortova et al., 2014; Ibrahim et al., 2010; Kortagere, 2012;
Sommerville et al., 2013; Szabo and Finney, 2017). Other strategies
employed by T. gondii to establish an infection include secretion of ef-
fectors that interfere with host’s signaling pathways (Hakimi et al.,
2017), manipulation of the migratory ability of infected host cells
(Kanatani et al., 2017), inhibition of apoptosis of host cells (Chavarría-
Smith and Vance, 2015), avoiding autophagy (Portillo et al., 2017), and
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altering host cell cycle (Francia and Striepen, 2014; Lüder and Rahman,
2017). This intricate level of interaction between T. gondii and host cells
highlights the importance of understanding the pathogenesis of T.
gondii infection.
The mitogen-activated protein kinase (MAPK)/ERK pathway plays
roles in the proliferation, differentiation, and apoptosis of mammalian
cells (Cargnello and Roux, 2011; Kyosseva, 2004). Several MAPK/ERK
proteins have been identified in protozoa, such as Giardia lamblia (Ellis
et al., 2003), Leishmania mexicana (Bengs et al., 2005), Plasmodium
falciparum (Lye et al., 2006), and T. gondii (Brumlik et al., 2004; Huang
et al., 2011), indicating the presence of this mammalian-like MAPK/
ERK signaling pathway in various parasites. Also, two MAPK/ERK
proteins have been identified in T. gondii: TgMAPK1, a stress-response
MAPK, which is an important virulence determinant that affects T.
gondii stage differentiation and proliferation (Brumlik et al., 2004,
2013) and putative TgERK7 protein (also known as TgMAPK2), which is
associated with intracellular proliferation of T. gondii, where erk7 gene-
knockout strain exhibited extended asexual cycles within host cells (Li
et al., 2016). These findings suggest that TgERK7 protein is a critical
determinant of T. gondii pathogenesis and may play a role in stimulation
of host immune responses during T. gondii infection, and can therefore
be a candidate vaccine antigen.
In this study, a recombinant TgERK7 protein-based vaccine was
tested in BALB/c mice in order to examine the potential of TgERK7 to
induce effective immunity that protects against T. gondii infection. We
also investigated several immune response parameters, such as anti-
body (Ab) titers, cytokine levels, T-cell populations in order to evaluate
the extent of the immune response that this vaccine can elicit. The
immunogenicity of five predicted peptides of TgERK7 and the full
length TgERK7 was examined using sera from immunized mice.
Furthermore, the growth inhibitory activity of antibodies raised against
the five TgERK7 peptides against T. gondii was studied in vitro.
2. Materials and methods
2.1. Cell lines, parasites and animals
African green monkey kidney (Vero) cells were used as feeder cells
to maintain T. gondii GT1 strain (Genotype I). Human foreskin fibro-
blast (HFF) cells were used to evaluate parasite replication in vitro.
Culture conditions, including cell passaging, were performed as pre-
viously described (Braun et al., 2013; Li et al., 2016). Density gradient
centrifugation using Percoll (GE Healthcare, Uppsala, Sweden) was
used to isolate the tachyzoites as previously described (Omata et al.,
1999). The cysts of T. gondii PRU strain (Genotype II) were isolated
from brain homogenates of chronically infected Kunming mice. Purified
tachyzoites and brain cysts of T. gondii were counted microscopically
using a hemocytometer and used in the subsequent experiments.
Six- to 8-week-old female BALB/c mice were purchased from the
Laboratory Animal Center of Lanzhou University (Lanzhou, China).
Mouse food and bedding materials were provided by Beijing Keao
corporation (http://u6452366.b2bname.com). Mice were housed in
cages under specific-pathogen-free (SPF) conditions in high-density
Touch Screen Mouse IVC (FENGSHI, Suzhou, China) without any
treatment for a week, in order to allow time for acclimatization and
reduce stress before immunization. The experimental protocols were
approved by the Animal Ethics and Administration Committee of
Lanzhou Veterinary Research Institute, Chinese Academy of
Agricultural Sciences (Approval No. LVRIAEC2012−011). All experi-
ments were conducted in accordance with the guidelines of the Animal
Ethics Procedures of the People's Republic of China. Every effort was
made to avoid any unnecessary discomfort and pain to the animals.
2.2. Construction of pET-erk7 plasmid and protein expression
The coding sequence of T. gondii erk7 gene was amplified by PCR
using two specific primers (forward primer: 5′-GGAATTCCATATG
AAACACCATCATCATCATCATCAGATGAGTGACGAGGTCGACAAAC-3′ and
reverse primer: 5′-CCGGAATTCTTATCAGCTGTTGTATGTCTTG
GAC-3′). This primer set was designed according to the sequence of the
reference T. gondii GT1 strain (ToxoDB: TGGT1_233010) and included
NdeI and EcoRI restriction sites (underlined) and the his-tag (double
underlined). Total RNA of GT1 tachyzoites was extracted using the
E.Z.N.A.® Total RNA Kit I (Omega, Georgia, USA).
The amplification reaction was performed according to the in-
structions of the PrimeScript™ One Step RT-PCR Kit Ver2 (TaKaRa,
Dalian, China) as follows: reverse transcription at 50 °C for 0.5 h; RTase
inactivation at 95 °C for 2min; followed by 35 cycles with initial de-
naturation at 95 °C for 1min, annealing at 56 °C for 0.5 min, and ex-
tension at 72 °C for 2min; and a final extension at 72 °C for 10min. The
amplified product was isolated using the E.Z.N.A.® Gel Extraction Kit
(Omega) and ligated into the pMD18-T simple linear vector (TaKaRa) to
construct the pMD-erk7 plasmid. A plasmid with erk7 sequence was cut
with the restriction enzymes NdeI and EcoRI (NEB, Beijing, China) and
ligated into the pET-30a prokaryotic expression vector that was re-
stricted with the same restriction enzymes (Novagen, Wisconsin, USA).
The sequence of the resulting recombinant pET-erk7 plasmid was con-
firmed by DNA sequencing. The recombinant pET-erk7 plasmid con-
taining the TgERK7 was transformed into chemically competent
Escherichia coli BL21(DE3) cells, where protein expression was per-
formed by inducing the lac promoter for expression of T7 RNA poly-
merase with isopropyl-β-D-thiogalactoside (IPTG, Promega, Wisconsin,
USA). The expressed TgERK7 protein with N-terminal 6 × His tags was
purified using chromatography column packed with 5mL of Ni-NTA
His%Bind® Resin (Novagen), according to the manufacturer's instruc-
tion.
2.3. Generation of peptide-specific antibodies
The amino acid sequence of the putative TgERK7 protein was de-
duced from T. gondii erk7 gene (ToxoDB: TGGT1_233010) using the
DNASTAR software (http://www.dnastar.com/), and five antigenic
epitopes were selected based on the flexible region, surface probability,
hydrophilicity and antigenic index analyses (Antunes et al., 2015;
Berzofsky, 1985); these are shown in Table 1. The synthesis, purifica-
tion and conjugation with Keyhole Limpet Hemocyanin (KLH) of the
five peptides were performed by the SBS Genetech Co., Ltd. (Beijing,
China). The production of rabbit polyclonal antibodies against these
five peptides, was performed according to the standard 70-day rabbit
immunization protocol provided by Thermo Fisher Scientific Inc.
(https://www.thermofisher.com). All antibodies (Table 1) were pur-
ified using BeaverBeads™ Protein A/G Matrix Antibody Purification Kit
(BeaverBio, Suzhou, China).
2.4. SDS-PAGE and Western blot analysis
The expressed protein in the lysates obtained from bacterial cells
transfected with the recombinant pET-erk7 plasmid or the empty pET-
30a plasmid, was analyzed via sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and Western blotting as previously
described (Nabi et al., 2017). For Western blot analysis, the separated
protein was electrophoretically transferred to a polyvinylidene fluoride
Table 1
The details of TgERK7 peptides and the corresponding antibodies.
Peptide Sequence (N′ - C′) Location Corresponding antibody
A DEVDKHVLRKYD 3−14 αA
B TGRPSPEDVDAVK 237−249 αB
C IKKKHDQRRHRTA 346−358 αC
D GSFVRDRPPAYA 461−472 αD
E HGPVRAKTDTHT 647−658 αE
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(PVDF) membrane. The membranes were incubated with a 1:1,000
dilution of rabbit anti-T. gondii TgERK7 peptide A-specific Ab (αA)
overnight. Then, goat anti-rabbit IgG (H+ L) secondary Ab conjugated
to horseradish peroxidase (HRP) was used (1:1,000 dilution), and the
band was visualized using a DAB horseradish peroxidase color devel-
opment kit.
2.5. Mouse immunization
Vaccine formulation was prepared by mixing TgERK7 (70 μg/100 μl
sterile phosphate-buffered saline; PBS) in 100 μl of Freund's adjuvant
(FA) (Sigma, Missouri, USA). Freund's complete adjuvant (FCA) was
used in the first two immunization doses and Freund's incomplete ad-
juvant (FIA) was used in three booster immunization doses. Each mouse
in the vaccinated group (n=23 mice) received 100 μl of the ad-
juvanted recombinant protein (TgERK7+FA) delivered via in-
tramuscular (i.m.) injection and subcutaneously (s.c.) in the left and
right posterior thighs and around the neck, weekly for 5 weeks. The
control (PBS+FA) group (n=23 mice) were injected in a similar
manner, but with 100 μl of PBS emulsified in the same Freund's ad-
juvants only without TgERK7. Mice in the third group (n=23 mice)
were left untreated (negative control). Further details of the vaccination
schedules are summarized in Table 2.
2.6. Sample collection
Blood (300 μl) was collected from the tail vein of three mice per
group into a heparinized tube. Blood samples were collected prior to
immunization and then at 2, 3, 4 and 6 weeks after the first im-
munization (Table 2). Collected blood samples were allowed to clot at
37 °C for 1 h, followed by the removal of clots by centrifugation at 500
xg for 10min. Sera were stored at −20 °C until used for determination
of total IgG Ab titers, anti-full length TgERK7 Ab titers, and TgERK7
peptide-specific Ab titers by an enzyme-linked immunosorbent assay
(ELISA).
Two weeks post the final/fifth immunization, blood samples were
collected from four mice per group to measure the level of cytokines
induced after the completion of the immunization schedule (Table 2).
Then, mice were euthanized by exposure to CO2 and their spleens were
harvested aseptically. A single-cell suspension of erythrocyte-free
splenocytes was prepared by gently pressing the spleen through a
0.2 μM mesh cell strainer. The splenocyte cultures were maintained in
RPMI 1640 medium containing penicillin-streptomycin, sodium pyr-
uvate, nonessential amino acids and 1% normal mouse serum.
2.7. Humoral responses
The total IgG Ab titers elicited by TgERK7 immunization in the
mouse sera was determined in 96-well flat-bottom microtiter plates
using SBA Clonotyping™ System/HRP Kit (Southern Biotech,
Birmingham, AL, USA) essentially as previously described (Li et al.,
2014). We also examined whether the antibodies elicited by im-
munization would recognize each of the five TgERK7-specific peptides
(Table 1) and the full-length TgERK7 protein. Briefly, 1 μg of capture Ab
provided in the kit, 1 μg of each TgERK7 peptide, or equal amount of
full-length TgERK7 protein expressed in vitro diluted in 100 μl of PBS
(pH 7.4) was adsorbed to the ELISA plate. The plate was washed with
PBS containing 0.05 % Tween 20 (PBS-T) and blocked with PBS con-
taining 1% bovine serum albumin (BSA) for 1 h. After blocking, 5 μl of
serum sample diluted with 95 μl of PBS were added into the wells of
plate and incubated for∼ 1 h at room temperature with gentle shaking.
After washing, each well received 100 μl of HRP conjugated anti-mouse
IgG (1:250 dilution) and incubated overnight at 4 °C, and used for de-
tection of the bound Abs. Binding was visualized by incubating with
100 μl of substrate solution (pH 4.0) (0.03 % H2O2, 1.5 % ABTS, 1.05 %
citrate substrate buffer). Absorbance was measured at 450 nm (OD450)
using ELISA reader (Bio-TekEL × 800, USA). All analyses were per-
formed in triplicate, with appropriate positive and negative controls.
2.8. Cytokine detection
The concentrations of interferon-gamma (IFN-γ), interleukin 2 (IL-
2), IL-4, IL-6, IL-10, IL-12p70, IL-23, monocyte chemoattractant pro-
tein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) were measured
in the sera obtained from four mice per group, two weeks after the final
immunization dose (Table 2). Analysis was carried out using the LE-
GEND MAX™ Mouse ELISA Kits (Biolegend, San Diego, USA), as per the
manufacturer’s instructions. The minimum detection levels of the kits
were: 8.0 pg/mL for IFN-γ, 0.9 pg/mL for IL-2, 0.5 pg/mL for IL-4,
2.0 pg/mL for IL-6, 2.7 pg/mL for IL-10, 0.5 pg/mL for IL-12p70,
4.8 pg/mL for IL-23, 3.5 pg/mL for MCP-1, and 1.5 pg/mL for TNF-α.
2.9. Flow cytometry measurement
The percentage of two subclasses (CD4+ and CD8+) of T lympho-
cytes in the single cell suspensions from mouse spleen was determined
using flow cytometry, as previously described (Li et al., 2014). Briefly,
cell viability was determined by 0.04 % trypan blue (Bio-Rad, Cali-
fornia, USA) and 106 viable cells were suspended in 100 μl of PBS
containing 2% fetal bovine serum (Invitrogen, California, USA). Cells
were stained for 30min at 4 °C in the dark with directly conjugated
antibodies. Specifically, cells were stained using the following cell
surface markers: phycoerythrin (PE)-labeled anti-mouse CD3e (5 μg/
mL), allophycocyanin (APC)-labeled anti-mouse CD4 (5 μg/mL) and
fluorescein isothiocyanate (FITC)-labeled anti-mouse CD8a (5 μg/mL)
antibodies according to the manufacturer’s instructions (eBioscience,
San Diego, USA). Lymphocytes were washed twice with PBS by cen-
trifugation at 250 × g for 5min and re-suspended in 300 μl of
Table 2
Details of immunization schedules and parasite challenge studies in BALB/c mice.
Group Treatments Group
size
Route of
administration
Mice used in Ab analysisa Mice used in T cell–mediated immunity analysisb Challenged
Mice (n)
PBS/TgERK7 FCA/FIA
Negative control – – 23 – 3 4 8c, 8d
PBS+ FA 100 μl 100 μl 23 i.m. & s.c. 3 4 8c, 8d
TgERK7+FA 70 μg 100 μl 23 i.m. & s.c. 3 4 8c, 8d
FA, Freund’s adjuvant; FCA/FIA, Freund’s complete/incomplete adjuvant; i.m., intramuscular injection in the thighs; s.c., subcutaneous injection around the neck.
a Blood samples from three mice per group were collected from the tail vein prior to immunization and then at 2, 3, 4 and 6 weeks post the first immunization, to
separate sera for determination of antibody (Ab) titers.
b To investigate the serum cytokines and T lymphocyte subclasses in spleen, blood samples from four mice per group were collected from the tail vein; and spleens
were aseptically removed, for preparation of erythrocyte-free single-cell suspensions 2 weeks post the final immunization.
c Two weeks post the final immunization, 8 mice per group were intraperitoneally challenged with 1000 tachyzoites of T. gondii GT1 strain.
d Two weeks post the final immunization, a further set of 8 mice per group were orally inoculated with 20 cysts of T. gondii PRU isolate.
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fluorescein-activated cell sorter (FACS) buffer (PBS supplemented with
1% BSA+0.1 % sodium azide), then fixed with 2% paraformaldehyde.
Analysis was performed with a FACScan flow cytometer (Becton Dick-
inson, San Diego, CA) and data were analyzed using SYSTEM II soft-
ware (Coulter).
2.10. Mouse challenge experiments
Two weeks after the final/fifth immunization dose, eight mice from
each group were challenged intraperitoneally (i.p.) with 103 T. gondii
GT1 tachyzoites per mouse, to test protection against acute infection.
The mortality of mice was recorded daily, until all infected mice have
died. Also, another set of eight mice per group were infected orally with
20 cysts of PRU strain. Four weeks post infection with PRU strain,
brains of mice from vaccinated and non-vaccinated (control) groups
were removed, and each brain was triturated in 1mL of PBS. The
number of cysts in 6–12 aliquots (20 μl each) of brain suspensions was
counted microscopically, and the average number of cysts was de-
termined for each mouse. Further details of the challenge experiments
are shown in Table 2.
2.11. In vitro replication of T. gondii
Two experiments were performed to investigate the inhibitory effect
of the individually purified peptide-specific antibodies on the in-
tracellular multiplication of T. gondii. In the first experiment, the pur-
ified antibodies were transfected into HFF cells using Pro-Ject™ Protein
Transfection Reagent (Pierce Biotechnology, Illinois, USA). First, we
examined the efficiency of transfection by measuring the antibodies in
the transfected HFF cells. Briefly, transfected HFF cells were digested
using 0.25 % trypsin (Transgen, Beijing, China) and a VCX750 ultra-
sonic processor (Sonics, Connecticut, USA). The supernatant was se-
parated by centrifugation at 2000 × g for 10min, and the level of Ab
subtypes (αA, αB, αC, αD and αE) was determined by ELISA assay - as
described above. Cells transfected with an equal volume of serum-free
medium (SFM) were used as a negative control. Next, HFF cells trans-
fected with peptide-specific antibodies or SFM were cultured on cover
slips (1× 106/well) in 24-well plates. The plates were incubated at
37 °C for 4 h, followed by washing three times with SFM. Cells were
infected with T. gondii GT1 strain (106 tachyzoites in 1mL of serum-
containing medium) at a multiplicity of infection (MOI) of 1 (1 parasite
to 1 host cell). In the second experiment, 106 tachyzoites were in-
cubated with 500 μl of SFM containing 60 μg of each of the peptide-
specific antibodies at 37 °C for 20min. Ab-treated tachyzoites were then
used to infect HFF cell monolayers in 24-well plate at MOI 1. For both
experiments, the parasite intracellular proliferation was evaluated at
12, 24 and 36 h post infection (hpi). The number of tachyzoites per
parasitophorous vacuole (PV) was counted by microscopy and at least
100 vacuoles were examined per sample. The parasites that have failed
cytokinesis were counted as two, and PVs containing one tachyzoite at
36 hpi were not included in the count. The average from three in-
dependent experiments was determined. We further examined the early
events of the parasite growth cycles (e.g., invasion and attachment of
HFF cells) in order to identify which phase of the parasite infection
cycle has been impacted by the anti-T. gondii activity of the peptide-
specific Ab. This analysis involved the peptide A-specific Ab because it
was the only Ab that showed significant inhibitory effect on the parasite
proliferation compared to control. The invasion and attachment assays
were performed using dual immunofluorescence assays (IFA) (α-
TgSAG1 antibody prior to permeabilization and αTgGRA7 antibody
after permeabilization) to allow the differentiation between extra-
cellular and intracellular parasites, essentially as previously described
in our recent work (Li et al., 2020).
2.12. Protein-protein interaction (PPI) analysis
To identify all protein interactions betweeen putaive TgERK7 and
other proteins in T. gondii, we queried STRING Database using the
function “protein by sequence search”, selecting T. gondii as organism
and using T. gondii’s MAPK2 sequence as input (Szklarczyk et al., 2017).
The resultant interactions were presented in a network using Cytoscape
(Shannon et al., 2003). Next, we used protein BLAST program to
identify human and mouse proteins that are most similar to TgERK7
sequence. Using the most TgERK7-homologous human and mouse
proteins, we obtained the known interactions from the following da-
tabases: Intact (Orchard et al., 2014), String (Szklarczyk et al., 2017),
BioPlex (Huttlin et al., 2017) and BioGrid (Chatr-Aryamontri et al.,
2017). The resultant lists of interacting proteins were used to genarate
networks to show the interactions between TgERK7 homologous, and
human and mouse proteins. To identify the functional annotations of
the proteins involved in the PPI networks, we performed Gene Ontology
(GO) enrichment analysis using FuncAssociate 3.0 (Berriz et al., 2003).
2.13. In silico modelling analysis
Structural information is unavailable for erk7 and we generated
initial conformations by homology modelling using I-TASSER and
Phyre2 (Kelley et al., 2015; Zhang, 2008). The full-length erk7 was not
possible due to the lack of templates in the C-terminal part of the
proteins. However, the N-terminal domain 1−351 has been character-
ized in orthologues, which provides suitable set of templates and we
were able to generate a set of homology models with good reliability.
The highest similarity orthologue was a MAP kinase erk2 with a TM
score of 0.485 and the top 10 ranked with TM score of 4.448 or higher
(Zhang et al., 1994). All models agreed structurally with each other
showing expected N-terminal variation due to reduced restraints.
The top N-terminal erk7 1−351 model from I-TASSER was prepared
for MD simulations using CHARMM-GUI (Jo et al., 2008). In parallel,
peptide erk7 3−14 was excised from the model and also prepared for
MD simulations identically to the N-terminal in a water box with 12.5A
separation from each end of the putative protein/peptide in 150mM
KCl to isolate the Debye layers of the protein from images in the peri-
odic boundary conditions. The systems were set up for simulations at
310 K using a CHARMM-36 force field. Equilibration under NVT and
production runs under NPT restraints was carried out using NAMD 2.12
(Phillips et al., 2005). All equilibration runs were done on a U1 server
with K80 and K40 Tesla GPUs while production was done in both vector
mode on the U1 and using the scalar parallel architecture of the Uni-
versity of Nottingham HPC. Trajectory analysis and visualization were
done using UCSF Chimera and VMD (Pettersen et al., 2004; Phillips
et al., 2005).
2.14. Statistical analysis
Data collected from at least three independent biological replicates
per experiment were analyzed using the SPSS Statistics 19.0 software
package (SPSS Inc., Illinois, USA). The results are presented as the mean
and standard deviation (Mean ± SD). Differences in the data (e.g. Ab
responses, cytokine production, flow cytometric analysis and in vitro
parasite proliferation) between all the groups were examined by one-
way ANOVA. (*P < 0.05, **P < 0.01, and ***P < 0.001).
3. Results
3.1. Cloning and expression of putative TgERK7 protein
The pET-erk7 plasmid was successfully constructed and induced to
express recombinant putative TgERK7 protein. SDS-PAGE and Western
blot analysis of the lysate prepared from E. coli BL21 (DE3) transfected
with pET-erk7 vector showed a single band with an estimated molecular
Z.-Y. Li, et al. International Journal of Medical Microbiology 310 (2020) 151432
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mass of∼74.4 kDa (Fig. 1). However, no band of TgERK7 was detected
in the lysate of bacterial cells transfected with the control pET-30a
plasmid.
3.2. Total IgG, full length TgERK7 and peptide-specific Ab responses
Five antigenic peptides of TgERK7 protein were conjugated with
KLH, and used to immunize rabbits for production of peptide-specific
antibodies (αA, αB, αC, αD and αE, as shown in Table 1). The five
TgERK7 peptides, the full-length TgERK7 protein expressed in vitro and
the capture Ab provided in the ELISA kit were used to coat ELISA plate
for detection of the levels of TgERK7-specific Abs (including full-length
protein and five peptides) and total immunoglobulin G (IgG) titers in
the serum samples collected at 0 (pre-immunization serum), 2, 3, 4, and
6 weeks after the first immunization. The level of anti-peptide A Ab in
TgERK7+FA-immunized mice was significantly increased compared
with that of control mice, starting from three weeks post first im-
munization (P < 0.05) (Fig. 2A). Although some significant differ-
ences in the levels of the other four peptide-specific Abs were detected
in the TgERK7+FA-immunized group compared with the pre-im-
munization serum, these differences were not statistically significant
when compared to PBS+FA immunized group (e.g. P = 0.5282 at 3
week, P= 0.6624 at 4 week, and P= 0.1689 at 6 week for anti-peptide
B; P = 0.2836 at 3 week for anti-peptide C; P = 0.4348 at 2 week, and
P = 0.4306 at 4 week for anti-peptide D; and P = 0.5797 at 4 week
post the first immunization for anti-peptide E) (Fig. 2B-2E). Likewise,
no significant difference was detected in the levels of anti-full-length
TgERK7 or total IgG antibodies between immunized and non-im-
munized mice (P > 0.05) (Fig. 2F-2 G). These results show that the
effect of TgERK7 immunization on humoral response (total IgG, Abs
against full-length TgERK7 and four peptides B, C, D and E) was com-
parable to the effect immunization using Freund's adjuvant only.
3.3. Cytokines induced by immunization
Levels of nine cytokines were determined in the sera of four mice
from each group two weeks after the final immunization dose. The
ELISA plates were read at 450 nm, and the absorbance was transformed
to pg/mL using the calibration curves generated using the cytokine
standards provided in the kits. The results showed that immunization
elicited multifunctional T cell responses, where immune cells simulta-
neously produced a mixture of cytokines. As shown in Fig. 3, compared
to the levels in the sera of negative control mice, eight cytokines in the
sera of TgERK7+FA-immunized mice were significantly elevated (P =
0.0054 for IFN-γ; P= 0.0152 for IL-2; P= 0.0142 for IL-4; P= 0.0007
for IL-10; P = 0.0304 for IL-12p70; P = 0.0018 for IL-23; P = 0.0473
for MCP-1; and P = 0.0119 for TNF-α). Four of these cytokines were
also significantly increased in the mouse group injected with PBS+ FA
compared to negative control (P= 0.0013 for IL-10; P= 0.0474 for
IL-12p70; P= 0.0258 for IL-23; and P= 0.0198 for TNF-α). In com-
parison to the PBS+FA group, concentrations of six cytokines were
elevated in the TgERK7+FA-immunized group (P= 0.0316 for IFN-γ; P
= 0.0492 for IL-2; P = 0.0134 for IL-4; P = 0.0229 for IL-10; P =
0.0064 for IL-23; and P = 0.0195 for TNF-α) (Fig. 3). No significant
difference was detected between TgERK7+FA-immunized group and
PBS+FA group for IL-6, IL-12p70 or MCP-1 (P > 0.05).
3.4. TgERK7 induced CD3e+CD4+ T lymphocytes in spleen
We investigated whether the putative TgERK7 protein can induce T
lymphocytes in the mouse spleen two weeks after the final immuniza-
tion dose. The subclasses of T lymphocytes (CD3e+CD4+ T cell and
CD3e+CD8a+ T cells) in single-cell suspensions obtained from spleen of
four mice per group were examined using flow cytometry. The number
of CD3e+CD4+ T cells were significantly higher in the (TgERK7+FA)-
immunized mice (%: 5.38 ± 1.57, P = 0.0211), when compared to
mice in the negative control group (%: 0.48 ± 0.13). However, no
difference was detected between mice vaccinated with TgERK7+FA (P
= 0.3225) and mice vaccinated with PBS+FA (%: 10.43 ± 4.16)
(Fig. 4A, 4C). In regard to CD3e+CD8a+ T lymphocytes, no difference
was detected between the negative control mice (%: 4.43 ± 0.45) and
mice treated with TgERK7+FA (%: 3.90 ± 0.09, P = 0.2962) or
PBS+FA (%: 5.60 ± 0.21, P = 0.0561). However CD3e+CD8a+ T
cells in TgERK7+FA group were significantly decreased compared to
mice vaccinated with PBS+FA (P = 0.0017) (Fig. 4B, 4D). Compared
with negative control mice (0.11 ± 0.04), the ratios of CD3e+CD4+ T/
CD3e+CD8a+ T in (TgERK7+FA)-immunized mice (1.38 ± 0.42, P =
0.0232) were significantly increased; however there was no difference
between the PBS+ FA group (1.80 ± 0.69, P = 0.0922), and mice in
the two other groups (P = 0.6280) (Fig. 4E).
3.5. Anti-T. gondii effect of TgERK7peptide- specific Abs
We examined the anti-T. gondii activities of five peptide-specific
antibodies on the intracellular proliferation of T. gondii by incubating
the parasite with each Ab prior of infection or by infecting host cells
that have been already transfected with Ab. The efficiency of Ab
transfection was confirmed using ELISA as shown in Fig. 5A. The effect
Fig. 1. In vitro expression and detection of TgERK7 protein. The
putative TgERK7 protein was expressed in E. coli BL21 (DE3) strain
and confirmed by (A) SDS-PAGE and (B) Western blot analysis.
The rabbit anti-T. gondii TgERK7 peptide A-specific Ab (αA) was
used as the primary Ab in the Western blot analysis. Only one
band of ∼74.4 kDa (indicated by asterisk) was detected in the
lysate of pET-erk7-transfected cells, which was absent in the
control cells transfected with empty pET-30a plasmid. Lanes: M,
molecular mass (KDa) standard protein marker; 1, lysate prepared
from E. coli BL21 (DE3) transfected with pET-30a empty vector; 2,
lysate prepared from E. coli BL21 (DE3) transfected with the pET-
erk7 vector; 3, lysate shown in lane 2 after purification using Ni-
NTA His·Bind® Resin (Novagen).
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Fig. 2. Antibody (Ab) responses after five immunization doses using putative TgERK7 protein. Levels of specific antibodies against (A) TgERK7 peptide A, (B) TgERK7
peptide B, (C) TgERK7 peptide C, (D) TgERK7 peptide D, (E) TgERK7 peptide E, (F) full-length putative TgERK7, and (G) total IgG were determined at OD450. Ab titers
were determined in the sera of TgERK7+FA-immunized group and control (PBS+ FA-treated and untreated negative control) groups (n=3/group) at 0 (pre-
immune serum), 2, 3, 4, and 6 weeks after the first immunization. The anti-TgERK7 peptide A antibodies progressively increased over the course of the immunization
period. Data points represent the mean values, with error bars indicating the standard deviations. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
FA indicates Freund’s adjuvant.
Fig. 3. TgERK7 immunization induced serum cytokines in immunized mice. The concentrations of nine cytokines (IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-23, MCP-
1, and TNF-α) in the mouse serum were determined by ELISA. ANOVA analysis of the data show that the cytokine concentrations at 2 weeks after the final
immunization were significantly higher than that of control mice. Standard deviations are indicated by error bars. ns, no significant difference; *, P < 0.05; **, P <
0.01; ***, P < 0.001. FA denotes Freund’s adjuvant.
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of treatment with different Abs on the intracellular proliferation of T.
gondii GT1 tachyzoites within HFF cells was investigated at three time
points (12, 24 and 36 h) after infection. Compared to the control, sig-
nificant delay in the proliferation of T. gondii was detected when the
parasite was incubated with anti-peptide A Ab prior to infection (P =
0.0025 at 12 h; P = 0.00016 at 24 h; and P = 6.3×10−11 at 36 h)
(Fig. 5B). There was no difference between the other four peptide-
specific Abs (αB, αC, αD, αE) and the control. Likewise, no difference in
the parasite growth was detected between HFF cells transfected by any
of the five peptide-specific Abs and control HFF cells (P > 0.05)
(Fig. 5C). Prior incubation of tachyzoites with αA significantly reduced
the invasion of T. gondii from 30min onwards in a time-dependent
manner (P < 0.05; Fig. 5D). However, there was no significant dif-
ference in the parasite attachment at 15min post infection between αA-
treated group and control (P > 0.05; Fig. 5E). Based on these results,
we conclude that αA inhibits the intracellular proliferation of T. gondii
most likely via delaying the parasite’s invasion.
3.6. Successive immunizations protect mice against acute T. gondii infection
TgERK7-immunized and non-immunized (control) mice were chal-
lenged with 103 tachyzoites of T. gondii GT1 strain (Genotype I) or 20
cysts of PRU isolate (Genotype II), two weeks after the final im-
munization. The data showed that survival times of TgERK7+FA-
Fig. 4. The levels of T lymphocyte subclasses in spleen of mice 2-weeks post the final immunization dose with the putative TgERK7 analyzed using flow cytometry.
(A) CD3e+CD4+ T and (B) CD3e+CD8a+ T lymphocytes (mean ± SD) were distributed in the regions Q2 and Q2-1, respectively. The percentages of (C)
CD3e+CD4+ T and (D) CD3e+CD8a+ T cells in single-cell suspensions of splenocytes of mice two weeks after the final immunization. Responses from individual
mice are indicated using black triangles. (E) The ratio between CD3e+CD4+ T and CD3e+CD8a+ T cells. ns, not significant; *, P < 0.05; **, P < 0.01. FA indicates
Freund’s adjuvant.
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immunized mice (13.8 ± 3.4 d) were significantly higher, when
compared with the control mouse groups (9.1 ± 0.7 d, P= 0.0040 for
PBS+FA group; 9.5± 2.2 d, P= 0.0066 for negative control group).
No significant difference was detected in the mouse group treated with
PBS+FA (9.1±0.7 d) when compared with mice in the negative
control group (P = 0.6372). All infected mice had died within 19 days
post challenge (Fig. 6A). The mortality rates of mice infected with PRU
cysts 15 days post challenge were 4/8 (50 %) in mice immunized by
TgERK7+FA, 2/8 (25 %) in mice immunized by PBS+FA, and 8/8
(100 %) in the negative control mice. There was no significant differ-
ence in the survival times between the negative control mice
(12.0 ± 0.5 d) and mice immunized by TgERK7+FA (11.0 ± 0.4 d, P
(caption on next page)
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= 0.2515) or mice immunized with PBS+FA (11.0 ± 1.0 d, P =
0.4236) (Fig. 6B). However, the number of brain cysts in the survived
TgERK7+FA-immunized mice (500.0 ± 40.8, P = 0.00004) was sig-
nificantly reduced (P<0.001) when compared with the control group
(PBS+FA: 1166.7 ± 61.5) at four weeks post challenge with PRU
cysts (Fig. 6C). These results suggest that successive immunizations
with putative TgERK7 protein can enhance the survival of acutely in-
fected mice and significantly reduce the brain cyst burden in mice with
chronic T. gondii infection.
3.7. Protein-protein intercation networks
Using STRING Database, we identified 26 T. gondii protein interac-
tions (Fig. 7A), having TgMAPK2, as the most homologous protein in
the database, based on T. gondii sequence. The functional annotation of
proteins involved in this parasite-parasite protein intercation network is
shown in Table S1. TgERK7-homologous (TgMAPK2) seems to intercat
with proteins of the rhoptry kinase family (ROP7, ROP21, ROP31,
ROP35). The finding that TgERK7 intercats with protein serine/threo-
nine phosphatase (PSTP) (Uniprot Id: B9QE64) was interesting because
PSTP plays a role in the regulation of MAPK signaling. However whe-
ther or to what extent PSTP influences the phosphorylation of TgERK7
remains to be determined.
BLAST search identfied MAPK15 (Uniprot Id: Q8TD08), which is
also known as ERK7, as the human protein that is most closely related
to TgERK7. Both TgERK7 and MAPK15 have sequence similarity values
of a E-value of 5e-129, a query cover of 64 %, and a total score 395.
Using the MAPK15 protein as input to query the interaction databases
(Intact, String, BioPlex, and BioGrid), we obtained 25 pairwise protein
interactions with 21 human proteins (Fig. 7B). MAPK15 seems to have
bidirectional relationship with PCNA, CLIC3 and MAP1LC3B. The GO
enrichment analysis revealed that these 21 proteins are most
Fig. 5. Exposure of T. gondii tachyzoites to TgERK7 peptide A-specific antibody (Ab) prolonged their intracellular replication. (A) ELISA assay was used to confirm the
efficiency of transfection of peptide-specific Abs. Optical densities of HFF cells transfected with each of the five peptide-specific Abs were higher compared to control
HFF cells transfected with serum-free medium (SFM) only (P = 0.0111 for αA; P= 0.0045 for αB; P= 0.0213 for αC; P = 0.0312 for αD; and P= 0.0020 for αE).
No significant difference was detected between any two of HFF cells transfected with peptide-specific Abs (P > 0.05), showing the success of the Ab transfection.
The purified peptide-specific Abs were co-incubated with T. gondii GT1 tachyzoites (B) or transfected into HFF cells (C) prior to the infection and the level of parasite
proliferation was examined. The data show that T. gondii co-incubation with peptide A-specific A (αA) prolonged the intracellular proliferation of this parasite.
However, this observation was not detected when the parasite was incubated with Abs specific to any of the other 4 peptides (B, C, D and E) nor in HFF cells
transfected with any of the 5 peptide-specific Abs. The early events of T. gondii growth cycle, invasion (D) and attachment (E), were further analyzed by IFA using
αTgGRA7 and αTgSAG1 Abs. (D) Invasion of T. gondii tachyzoites incubated with αA was significantly delayed starting from 30min post infection compared to
control tachyzoites incubated with SFM prior to infection (P < 0.05). (E) There was no difference in the attachment of tachyzoites at 15min between αA-treated
and SFM-treated tachyzoites. These results suggest that αA-mediated reduction in the parasite proliferation is attributed to reduction in the parasite invasion. ns, not
significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Fig. 6. Five immunization doses with putative TgERK7 protein protected mice against acute infection and reduced brain cyst burden. (A) Survival of BALB/c mice
after intraperitoneal challenge with 103 tachyzoites of T. gondii GT1 strain 2-weeks after the fifth immunization dose. The survival time of TgERK7-immunized group
(13.8 ± 3.4 d) was significantly increased compared to the two control groups (9.1 ± 0.7 d for PBS+ FA and 9.5 ± 2.2 d for the negative control) (P < 0.01). (B)
Survival of the immunized mice following oral infection with 20 cysts of PRU strain 2-weeks after the fifth immunization dose. No significant difference was detected
between TgERK7-immunized group and PBS+ FA-immunized group (P > 0.05). (C) The number of T. gondii cysts in the brain of the survived mice four weeks post
challenge. The brain cyst number of TgERK7-immunized mice (500 ± 40.8) was significantly reduced, compared with that of the control PBS+ FA-immunized
group (1166.7 ± 61.5) (*** P < 0.001). Standard deviations are indicated by error bars. FA indicates Freund’s adjuvant.
Fig. 7. Protein-protein intercation networks. (A) Intercation of putative TgERK7 protein with other T. gondii proteins. MAPK2 represents the most homologous
protein to TgERK7 sequence. Blue arrows represent the principal interactions of MAPK2 node, whereas gray arrows denote second level interactions. (B) Human
(Homo Sapiens) protein interactions having MAPK15 (Uniprot Id: Q8TD08), the human homologous of T. gondii sequence, as an initial node. Red arrows represent
unidirectional relationship, whereas green arrows represent bidirectional relationship and the gray arrow represents an auto-relation. (C) Mouse (Mus Musculus)
protein interactions having MAPK15 as initial node, where MAPK15 (Uniprot Id: Q80Y86) is the murine homologous of TgERK7. Orange arrows represent uni-
directional relationship, whereas blue arrows represent bidirectional relationship and the gray arrow represents a self-relation.
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signficantly enriched in chaperone-mediated autophagy, nitric-oxide
synthase regulator activity, MHC class II protein complex binding, DNA
polymerase binding, and MHC protein complex binding. The full results
of functional annotation of intercating human proteins are shown in
Table S2.
BLAST search also revealed that Mus musculus MAPK15 (Uniprot Id:
Q80Y86) is the most closely related to TgERK7, having a E value of 4e-
133, a query cover of 57 % and a total score of 405. Using MAPK15
protein to obtain all known interactions with M. musculus proteins, we
obtained 28 interactions with 18 mouse proteins (Fig. 7C). The GO
enrichment analysis showed that the most relevant biological functions
of these interacting proteins are regulation of telomerase activity, reg-
ulation of telomere maintenance via telomerase, regulation of telomere
maintenance via telomere lengthening, positive regulation of DNA
biosynthetic process, and focal adhesion. The full results of functional
annotation of these interacting mouse proteins are shown in Table S3.
3.8. Computational modelling of the ERK7 putative protein
High performance computing approaches offer detailed insights into
the molecular mechanisms underpinning experimental observations of
genetic and phenotypic variations (Sloan et al., 2019). To understand
the molecular and structural differences that confer enhanced anti-
genicity to pep1 in solution in comparison to the same sequence as
3−14 part of erk7 we carried out MD simulations of the peptide A alone
and of the N-terminal fragment of erk7 1−351. We hypothesise that a
free peptide offers unrestricted antigen presentation in comparison to
the same sequence participating in the protein fold of erk7, where it is
sheltered by neighbouring motifs. Further to that, we propose that the
peptide in solution is structurally less restrained and can complement
an antibody challenge better than when embedded as a component of
the structured N-terminal erk7.
In the absence of structural data on erk7, homology modelling was
used to generate lead conformations for the protein and the isolated
peptide. The lead model from I-TASSER was selected for MD simula-
tions to anneal the models and remove residual conformational strain
inherited from modelling templates. Structure annealing was complete
within 100 ns of simulations for the N-terminal domain of erk7 1−351
and within 50 ns for pep1, where in both cases structural drift had
subsided in the late stages of the simulations and only stochastic noise
modulated a steady RMSD average (Fig. 8A).
To understand the conformational variation of the peptide backbone
within the protein and compare it to free peptide in solution we used
conformational cluster analysis over the periods of simulations.
Conformational clusters report metastable structural intermediates of a
molecular system during the time evolution of its structure, which can
interconvert and contribute to the dynamically averaged structure ob-
served after computational evolution is complete. Fig. 8B shows aligned
conformations from the top four clusters of the peptide erk7 4–13 as
part of the N-terminal domain erk7 1−351 along with end of trajectory
conformation. Structural members of the most populated clusters show
good conformational agreement with each other over the entire tra-
jectory, which shows that the peptide structure is stable within its erk7
cleft.
Despite this well-defined conformation as part of erk7, the peptide
3−14 shows some dynamic freedom compared to the rest of the protein
and undergoes transient excursions outside its cleft. At the start of the
MD trajectory the peptide erk7 4–13 was set into a groove of the N-
terminal domain erk7 1−351 following the homology model built on
similarity to a crystalline orthologue. Comparatively early in the evo-
lution, the N-terminus was freed from the groove in the protein domain
and continued evolving in an exchange process in transient contacts
with the rest of the domain (Fig. 8C). Such conformational excursions
present the peptide for IGG binding, which is hindered when the pep-
tide is nested into a protein groove. This explains why the peptide does
show some antigen activity even as part of the erk7 protein.
In contrast to peptide erk7 4–13, the conformation of pep1 in so-
lution is quite fluid and structural alignment shows significant con-
formational variations between the top four clusters (Fig. 8B). Besides
its greater conformational flexibility, the mean conformation of pep1
appears more closed with a reduced end-to-end distance. This is illu-
strated in the end-to-end radial distribution function (RDF), which re-
flects the fraction of time along the MD trajectory that the α-carbons of
the two end residues of the peptide spend a given distance apart
(Fig. 8D). In that regard the free peptide behaves as an intrinsically
disordered system with end-to-end distance primarily in the region of
9−10 Å but undergoing excursions from approximately 5 Å to nearly
28 Å. By contrast, the peptide erk7 4–13 as part of the N-terminal do-
main of erk7 1−351 is structured with tightly clustered end-to-end
distances around 15 Å. The functional consequence of this difference is
that the free peptide is flexible and accessible for binding invitations
from IGG and can respond to conformational variations as an in-
trinsically disordered protein. This explains its higher antigenicity
compared to the same sequence presented as part of erk7 (Dyson and
Wright, 2005) where peptide erk7 3−14 with N-terminal erk7 is shel-
tered with only transient antigen presentation.
4. Discussion
The objective of this study was to produce a recombinant TgERK7
protein and to examine its potential as a vaccine to improve the pro-
tective responses against T. gondii infection in BALB/c mice. Generating
balanced Th1 and Th2 immune responses is necessary for limiting T.
gondii proliferation, while in the meantime protecting the host from
severe inflammatory pathologies (Lüder and Rahman, 2017). There-
fore, we examined the serum levels of total anti-T. gondii IgG antibodies,
and antibodies produced against the full-length TgERK7 protein and
against five specific TgERK7 peptides. We also determined the con-
centrations of nine serum cytokines and the levels of T lymphocyte
subclasses in the spleen of immunized mice. We were interested in
finding out how immunization with TgERK7 protein can influence these
factors, which play important roles in mediating host response to T.
gondii infection (Fallahi et al., 2018; Rougier et al., 2017; Sasai et al.,
2018).
First, we determined the total IgG titers and full-length TgERK7-
specific Ab responses in mice following immunization with a re-
combinant TgERK7 protein using ELISA. Immunization with TgERK7
did not significantly alter the levels of total IgG titers or anti-full-length
putative TgERK7 Abs in the immunized mice compared to non-im-
munized (control) mice. We also used ELISAs to determine the re-
activity of five TgERK7-derived peptides to the sera of the immunized
mice and to reveal differences in Ab specificities in the post-im-
munization sera. Interestingly, Ab titers against TgERK7 peptide A
significantly increased in the sera of immunized mice compared to Ab
titers prior to immunization. Multiple immunizations in mice were
necessary to induce peptide A-specific Ab response of a significant
magnitude. This demonstrates that antigen-specific humoral immune
responses elicited following recombinant TgERK7 protein immunization
is driven by TgERK7 peptide A, which may not have been sufficient to
trigger a strong humoral response.
Cytokine analysis showed that cytokines such as IFN-γ and IL-
12p70, which play key roles in the protection against T. gondii infection,
were induced by successive immunizations with TgERK7 protein. T.
gondii induces a type 1 response mediated by the production of proin-
flammatory cytokines, such as IFN-γ by T cells and natural killer cells to
control acute infection caused by the rapidly proliferating tachyzoites
(Kamiyama and Hagiwara, 1982; Rytel and Jones, 1966). While cell-
mediated immunity is critical for the effective control of T. gondii in-
fection, the attenuation of the inflammatory response is also important
to ensure the maintenance of immune homeostasis, while limiting im-
mune pathology. In a previous study, IL-10-deficient C57BL/6 mice
exhibited elevated IL-12 levels, and increased TNF-α and IFN-γ
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responses, resulting in severe inflammatory pathologies (Gazzinelli
et al., 1996). Therefore, increased IL-10 level in our study may function
to balance the high IFN-γ response in mice following T. gondii infection.
The Th2-type cytokine IL-10 favors an attenuation of host defense
mechanism against T. gondii invasion, by restraining Th1-mediated in-
flammatory response, while maintaining a Th2 immune response
(Thouvenin et al., 1997). This balanced immune response seems to
protect the host and offers a supportive environment for the estab-
lishment of latent infection (Denkers and Gazzinelli, 1998).
T cells, major histocompatibility complex (MHC) class I-restricted
CD8+ T cells and MHC class II-restricted CD4+ T cells, are required for
protective immunity against T. gondii infection; and play key roles in
infection resolution and protection against reinfection (Gazzinelli et al.,
1992; Suzuki and Remington, 1988). CD8+ T cells have the capacity to
remove cysts from the brain of chronically infected mice (Ochiai et al.,
2016; Suzuki et al., 2010). Mice that lack T cells do not survive to the
chronic stage of infection, and depletion of T cells resulted in re-
activation of tissue cysts (Gazzinelli et al., 1992; Hunter et al., 1994). In
our study, the level of CD4+ T cells, but not CD8+ T cells in mouse
spleen was significantly induced by TgERK7 immunization. The de-
creased induction of CD8+ T lymphocyte may be related to the protein
used in immunization; even with FA boosting TgERK7 protein was not
good enough at eliciting a cytotoxic T cell response. It is intriguing that
the induction of CD8+ T cell was poor, but the vaccine still managed to
prolong the survival of mice after challenge with the virulent GT1 strain
(Genotype I) and also caused ∼ 50 % reduction in brain cyst burden
post challenge with the PRU strain (Genotype II). It remains paradoxical
to observe a significant decrease in the parasite burden in the brain of
immunized mice challenged with T. gondii PRU strain, despite the lack
of enhanced CD8+ T cell response.
When the inhibitory effect of αA on T. gondii growth in vitro was
investigated we found that asexual replication of T. gondii within HFF
cells was significantly prolonged when the parasite was incubated with
αA prior to infection. However, neither treatment with any of the an-
tibodies specific to any of the other four peptides (αB, αC, αD, αE) nor
transfecting cells with any of the five peptides showed any inhibitory
effect on T. gondii growth. These results suggest that inhibition of the
parasite growth was mediated by αA response, likely via impairment of
the biological functions of certain components that play a role in the
invasion and/or growth of T. gondii. As discussed above, although
TgERK7 immunization did not elicit high levels of total IgG, anti-full-
length TgERK7 Abs or specific Abs to the four peptides (B, C, D and E),
immunization induced a high level of anti-peptide A Abs. Also, our
results showed increased CD3e+CD4+ T lymphocyte proportion in
spleen of immunized mice. These results provide more evidence to
support the hypothesis that Abs produced against peptide A
Fig. 8. (A) Root mean square deviation, RMSD, in Å for N-terminal erk7 1-351 (top, 100 ns) and pep1 (bottom, 50 ns). Frame number is shown on the abscissa.
Annealing pf N-terminal erk7 1-351 ends around frame 350/500 or 70 ns, while the small pep1 anneals very quickly within the first few tens of ns. RMSD is
constrained within approximately 1 Å across the entire protein for N-terminal erk7 1-351, while RMSD readily fluctuated within 2 Å in the free peptide. (B) Aligned
average backbone conformations from top four clusters for erk7 3-14 (top left, blue) and pep1 (bottom left, orange). The peptide shows much better defined structure
as part of the N-terminal erk7 1-351 fragment but is very flexible in solution allowing it to respond to binding requests from conformationally dissimilar epitopes as
an intrinsically disordered peptide. The location of erk7 3-14 within the N-terminal domain erk7 1-351 is shown on the right from the last frame of 100 ns trajectory in
blue with the rest of the protein shown in cyan. (C) Frame-to-frame RMSD over the trajectory. Evolution of backbone conformation defines conformational clusters:
N-terminal erk7 1-351, last 50 ns (left); erk7 4-13, last 50 ns (middle); pep1, 50 ns (right). White shows low variation and black shows “hot” regions or significant
changes in RMSD. The intensity maps range from 1.3 to 4.8 Å for erk7 1-351 (left) through 0.9 to 5.7 Å for erk7 4-13 (middle) to 0.8 to 10.2 Å for pep1 (right). (D)
Pairwise radial distribution function, RDF, between the α−carbons of residues 4 and 13 in erk7 4-13 (top) and between α-carbons of residues 1-9 in pep1 (bottom)
over 100 and 50 ns trajectories. The peptide conformation within N-terminal erk7 1-351 is well-defined with tightly clustered end-to-end distance around 15 Å, while
the free peptide is intrinsically disordered with end-to-end distance primarily in the region of 9-10 Å but undergoing excursions from approximately 5 Å to nearly
28 Å.
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(DEVDKHVLRKYD) by TgERK7 immunization might have neutralized
the tachyzoite’s ability to invade and/or colonize host cells. Therefore,
it is likely that the protective effect of anti-peptide A Ab in acutely
infected and immunized mice may be attributed to αA-mediated neu-
tralization of functional key ERK7 peptide epitope(s). This humoral
immune response also seems effective for controlling the parasite
during chronic infection.
The finding that multiple immunizations induced only peptide A-
specific Ab response of a protective magnitude was unexpected.
Therefore, we attempted to reflect on the potential reasons as to why Ab
against peptide A seems to have the most potent anti-T. gondii activity.
Antigen presentation is described traditionally through crystal struc-
tures of antigen/Ab fragments that are frozen in time. The process of
recognition, however, is more complex and is guided by long-range
interactions, diffusion and segmental dynamics of both partners
(Abriata and Dal Peraro, 2015; Bretou et al., 2016). The dynamic pic-
ture presented in the MD simulations emphasizes the importance of
accessibility and flexibility of a simple antigen sequence (peptide A in
this case). The observed conformational flexibility of the N-terminal
peptide when liberated from the restrictions of a protein crustal ex-
plains its antigenicity and capacity to engage the antibody. Taking the
step further and releasing the sequence from its anchor point into a free,
disordered structure, markedly enhances its antigenicity and adapt-
ability to meet the conformational expectations of antibodies.
It would be important to understand why blocking ERK7 leads to
inhibition of the parasite invasion in vitro and protected mice against
acute and chronic infections. In T. gondii, two MAPK orthologs, desig-
nated as MAPK1 and MAPK2, have been shown to play roles in host-cell
attachment, bradyzoite differentiation and parasite replication (Cao
et al., 2016; Li et al., 2016). Severe developmental defects have been
described in T. gondii deficient in MAPK1 (Cao et al., 2016). Also, de-
letion of MAPK1 and MAPK2 in T. gondii type I tachyzoites rendered the
mutant strains less virulent in mice. Also, mice infected with mutant
strains exhibited low levels of IL-18, caspase-1, ASC and NLRP1/3,
decreased STAT3 phosphorylation and high levels of IFN-β and IL-10
transcripts as well as increased phosphorylation of STAT1. An earlier
study showed that during T. gondii infection in mice, MAPK1 and
MAPK2 sensitize the nucleotide-binding domain and leucine-rich re-
peat-containing protein NLRP1/3 inflammasomes that mediate mouse
resistance to infection (Wang et al., 2016). Findings obtained in the
present and previous studies support the evidence for the im-
munostimulatory role of the putative ERK7 protein in regulating T.
gondii parasite proliferation and in mediating host response to T. gondii
infection.
In conclusion, we investigated the potential of TgERK7 protein-
based immunization for conferring protection in BALB/c mice against
T. gondii infection. Immunization did not elicit potent humoral im-
munity as indicated by the lack of increased total IgG and anti-full-
length TgERK7 Ab levels following immunization. By contrast, TgERK7-
immunization induced significant increase in anti-peptide A Ab titers,
suggesting the immunogenicity of this peptide. Congruently, out of the
five TgERK7 peptides only anti-peptide A Ab exerted an inhibitory ac-
tivity against growth of T. gondii tachyzoites in vitro. Interestingly,
immune response induced by immunization with TgERK7 was sufficient
to impart protective immunity to T. gondii infection as evidenced by the
improved survival rate of BALB/c mice infected by virulent GT1 type I
strain and the considerable reduction of the parasite cyst burden in the
brains of mice infected by type II PRU strain. Further examination of
the possible therapeutic efficacy and immune correlates that underpin
the anti-parasitic activity of TgERK7 peptide A is warranted.
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